M2537

Mevastatin

≥98% (HPLC), 3-hydroxy 3-methyl glutaryl coenzyme(A) reductase (HMG-CoA reductase) inhibitor, powder or crystals

• Synonym(e): Compactin, ML-236B
• Empirische Formel (Hill-System): C₂₃H₃₄O₅
• CAS-Nummer: 73573-88-3
• Molekulargewicht: 390.51
• NACRES: NA.77
• PubChem Substance ID: 24278540
• UNSPSC Code: 12352200
• MDL number: MFCD05662341
• Beilstein/REAXYS Number: 1269441
• Assay: ≥98% (HPLC)
• Form: powder or crystals

Eigenschaften

• Produktname: Mevastatin, ≥98% (HPLC), powder or crystals
• Quality Segment: 200
• assay: ≥98% (HPLC)
• form: powder or crystals
• color: white to light yellow
• mp: 151 °C
• solubility: ethanol: 25-26 mg/mL, clear, colorless
• antibiotic activity spectrum: neoplastics
• mode of action: enzyme | inhibits
• originator: Daiichi-Sankyo
• storage temp.: 2-8°C
• SMILES string: [H][C@]12[C@H](CCC=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)[C@@H](C)CC
• InChI: 1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1
• InChI key: AJLFOPYRIVGYMJ-INTXDZFKSA-N
• Gene Information: human ... HMGCL(3155), HMGCR(3156) ; rat ... Hmgcr(25675)

Beschreibung

General description

Mevastatin is a polyketide that belongs to the class of statins. It contains a hydroxy-hexahydronaphthalene ring.

Chemical structure: statin

Application

Mevastatin has been used:

• to analyze its effects on chronic lymphocytic leukemia (CLL) cells by cytotoxic assay
• as a prenylation inhibitor to analyze its effects on human embryonic kidney (HEK) cells transfected with K-Ras
• as a statin agent to study its anti-cancer effect on human breast cancer cells and glioblastoma in vitro

Biochem/physiol Actions

Mevastatin is a selective inhibitor of 3-hydroxy 3-methyl glutaryl coenzyme(A) reductase (HMG-CoA reductase), a major enzyme involved in cholesterol synthesis. It acts as a cholesterol-lowering agent. Mevastatin is obtained from various species of fungi. It acts as an antiresorptive agent and has therapeutic effects to treat osteoporosis. Mevastatin inhibits bone resorption by triggering osteoclast apoptosis. It is also involved in the inhibition of prenylation of proteins such as Ras. Mevastatin increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels by blocking the geranylgeranylation of transcription factor Rho.

Features and Benefits

This compound was developed by Daiichi-Sankyo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)